Denali Therapeutics logo
Denali Therapeutics
DNLI | NASDAQ
Chart Builder DCF Calculator
$18.08
-$0.66 (-3.52%)
At close: Nov 16, 2026, 4:00 PM ET
$18.08
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Denali Therapeutics Company Profile

Company profile explained

Company Profile

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

Key Executives

Name Position
Ryan J. Watts Co-Founder, President, Chief Executive Officer & Director
Alexander O. Schuth Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary
Cindy Dunkle Chief People Officer
Chris Walsh General Counsel
Dana Andersen Chief Technical and Manufacturing Officer
Joe Lewcock Chief Scientific Officer
Katie Peng Chief Commercial Officer
Peter Chin Acting Chief Medical Officer & Head of Development

Latest SEC Filings

Date Type Title
Sep 09, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 03, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 04, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 28, 2026 8-K Current Report
Jul 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Denali Therapeutics
Denali Therapeutics logo
Country United States
IPO Date Dec 8, 2017
Industry Biotechnology
Sector Healthcare
Employees 503
CEO Ryan J. Watts

Contact Details

161 Oyster Point Boulevard South San Francisco, California 94080 United States

Stock Details

Ticker Symbol DNLI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001714899
CUSIP Number 24823R105
ISIN Number US24823R1059
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.